Paratarg-7, a frequent autoantigenic target, and all other autoantigenic targets of human paraproteins molecularly defined to date are hyperphosphorylated in the respective patients compared to healthy controls suggesting that hyperphosphorylation of autoantigenic paraprotein targets is a general mechanism underlying the pathogenesis of these paraproteins.
Introduction
Antigenic targets of paraproteins from patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström´s macroglobulinemia (WM) might play a role in the pathogenesis of these neoplasms; however, only few have been identified to date. We recently demonstrated that paratarg-7 is the target of ca. 15% of paraproteins of the IgA and IgG type from patients with MGUS and MM 1 , and p. 5 
Inhibitory experiments
Stably transfected lymphoblastoid cell lines were cultured in the presence of inhibitory compounds as indicated. After 5 days, cells were removed and analysed by IEF and immunoblot detection.
Isoelectric focusing
Washed LCLs were treated with lysis buffer (8M urea, 0.1 M NaH 2 PO 4 , 0.01 M TrisHCl, 0.1 % NP40), mixed with 2 x IEF loading buffer and subjected to isoelectric focussing using precast gels (Invitrogen IEF pH3-10). Analysis was done according manufacturers protocol (1h 100 V, 1h 200 V, 30min 500 V). After semi-dry blotting on PVDF membranes (450 mA, 1h), immunodetection was done using patients` or control serum. The membrane was blocked in TST/milk buffer (10% milk in 10 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween 20) overnight, washed and incubated for 1 h with serum in TST (paraprotein-containing patient´s serum at a dilution of 1:10 8 and control patients serum at a dilution of 1:10 3 ). After three washings in TST, the membranes were incubated for 1 h at RT with goat anti-human IgG POX-coupled antibody (Dianova) diluted 1:5,000 in TST, subsequently washed in TST followed by ECL-development.
Enzymatic treatment
LCLs were washed 3 x with PBS followed by lysis in LS buffer (10 mM TrisHCl pH8, 30 min 4°C). After increasing the concentration of TrisHCl to 100 mM, alkaline phosphatase was added (1U/µl per 500 µl lysate) and incubated at 37°C overnight. The phosphatase was inactivated by heating at 80°C for 10 min. Equal volumes of sample and loading buffer were mixed, followed by IEF and immunodetection as described above. For cleaving pP-7 by
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From p. 6 endopeptidases, LCLs were washed 3 x with PBS followed by lysis in LS buffer (10 mM TrisHCl pH8, 30 min 4°C). After changing to 100 mM TrisHCl/10mM CaCl 2 , chymotrypsin was incubated overnight at room temperature, and trypsin at 37°C. PBS without enzymes was used as control. Incubation was stopped by the addition of 2 mM PMSF. Endopeptidasetreated samples and controls were then submitted IEF followed by immunoblotting as described above.
Paratarg-7 deletion mutants
Paratarg-7 fragments were obtained by PCR amplification using suitable primers and verified by sequencing. These fragments were subcloned into the vector and expressed as described before 1 .
Site-directed mutagenesis
Using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla) and a paratarg-7 DNA fragment coding for FLAG-tagged amino acids 1 to 60, mutants were constructed in which the serines were changed to alanines (Ser17Ala, Ser21Ala, Ser17AlaSer21Ala). These mutants were stably transfected into HEK293 cells. Fragments of paratarg-7 were amplified by PCR using the primers listed below and full-length paratarg-7 as template followed by cloning into pSfi-FLAG as expression vector. 
Complementation assay
Total lysates of HEK cells expressing FLAG-tagged paratarg-7 fragments were prepared and inactivated by heating ("acceptor lysate"). Cells of healthy donors or patients were lysed with 10 mM Tris pH8 and centrifuged ("donor lysate"). Both lysates were co-incubated for 48h at 37°C and analysed by IEF and immunodetection using anti-FLAG-mAb.
Immunoprecipitation
Cell lysates were incubated with the first antibody at 4°C overnight. Antigen-antibody complexes were purified by protein-G chromatography, followed by gel electrophoresis and blotting. Immunostaining was done using a second antibody. For details of the antibodies see figure legends.
Quantitative PCR
LCLs from patients and healthy donors were used for the isolation of total RNA (Qiagen RNeasy Blood Kit). Reverse transcription was performed using Superscript II (Invitrogen) and oligo-dT primers according to the suppliers manual. Quantitative PCR was done on a Roche Lightcycler I using SYBR green and gene specific primers. Gene copy number quantification was done as described previously 9;10 .
Results

Paratarg-7 in lymphoblastoid cell lines (LCLs)
In MGUS/MM/WM patients with a paratarg-7 specific paraprotein and healthy carriers of hyperphosphorylated paratarg-7 (pP-7), pP-7 was hyperphosphorylated constitutively in lysates of whole peripheral blood, erythrocytes, neutrophils and lymphocytes, but also in EBV-transformed lymphoblastoid cell lines (LCL) derived from these patients. This allowed for the use of these LCLs as an unlimited cellular source for the experiments of this study.
Identification of the phosphorylation site responsible for the hyperphosphorylation of paratarg-7
To narrow down the location of the additional hyperphosphorylation(s), paratarg-7 was digested with trypsin and chymotrypsin. Digestion with chymotrypsin results in a fragment containing amino acids 1 to 40
(http://db.systemsbiology.net:8080/proteomicsToolkit/proteinDigest.html). Comparing patients and controls the additional phosphorylation was assigned to the fragment containing amino acids 1 to 40, which covers the region to which the patients´ paraproteins bind. This was indicated by a modified migration of the immunopositive chymotryptic fragment and an additional immunoreactive band in the tryptic digest of paratarg-7 derived from erythrocytes and separated by IEF (Fig. 1a) .
As shown previously, the immunogenic region of paratarg-7 was identified as a region spanning 15 amino acids (H2N-SLLASGRAPRRASSG-COOH) near the N-terminal end of the protein 1 . In further ELISA experiments with smaller overlapping paratarg-7 derived peptides, the region spanning the epitope was narrowed down to a peptide spanning from amino acids 16 to 25 (data not shown). In addition, as described above, isoelectric focussing showed that a chymotryptic fragment of paratarg-7 (amino acids 1 to 40) derived from patients was hyperphosphorylated when compared to the corresponding fragment of healthy donors. This was also shown for recombinant fragments containing amino acids 1 to 60 and amino acids 1 to 25, while no hyperphosphorylation was demonstrated in a fragment containing amino acids 20 to 60 (Fig. 1b) . Taking together, these findings demonstrate that amino acids 1 to 25 cover the paraprotein-binding epitope and the phosphorylation site which is responsible for the hyperphosphorylation of paratarg-7. This region contains two serines, one at position 17 and one at position 21. By site-directed mutagenesis of Ser17 and Ser21 to Ala17 and Ala21, respectively, followed by expression of these recombinant fragments and complementation assays using enzyme extracts derived from patients and healthy controls, Ser17 was identified as the site where hyperphosphorylation occurs (Fig. 1c+d) . Tyr124, another phosphorylation site described before by Rush et al.
11 , showed no difference between patients and healthy controls and was therefore excluded as being responsible for paratarg-7 hyperphosphorylation in the patients with paratarg-7 specific paraproteins. Fig. 2A ). This was confirmed by using highly specific PKCzeta pseudosubstrate as inhibitor 13 (Fig. 2B ). In addition, direct interaction of paratarg-7 and PKCzeta was demonstrated by coimmunoprecipitation experiments using LCLs (Fig 2D, Fig. 7 e, f). Finally, the direct interaction between PKCzeta and Ser17 of paratarg-7 was demonstrated by coimmunoprecipitation ( Fig. 2C ) of mutagenized peptide fragments as well as in in-vitro experiments using purified PKCzeta and paratarg-7 (Fig. 2E ). 
Hyperphosporylation of paratarg-7 by inactivation of PP2A
To test whether the observed hyperphosphorylation of paratarg-7 is due to a modified enzymatic activity in carriers of hyperphosphorylated paratarg-7, we transformed LCLs with a recombinant expression construct producing FLAG-tagged paratarg-7. After lysis and inactivation by heat, the "acceptor lysate" was incubated with a "donor lysate" which was obtained by lysis of the respective LCLs which had not been heat-inactivated. Using LCL extracts derived from a patient carrying pP-7 as acceptor and LCL extracts derived from a healthy donor carrying wild-type paratarg-7 as donor, phosphorylation and dephosphorylation of paratarg-7 was demonstrated (Fig. 4) . In a second experiment with reversed probes (acceptor lysate derived from LCLs of a healthy donor incubated with the extract derived from the LCLs of a pP-7 carrier), phosphorylation was demonstrated, but dephosphorylation (reversal to wild-type P-7) was not observed. This indicates that phosphorylation of paratarg-7 is operative, but dephosphorylation is inhibited in patients carrying pP-7.
Identification of the phosphatase responsible for the dephosphorylation of hyperphosphorylated paratarg-7
In T-cells from healthy donors carrying wtP-7 temporary hyperphosphorylation of paratarg-7 can be induced by stimulation with anti-CD3 and anti-CD28 antibodies (Fig. 5 ).
Hyperphosphorylation becomes detectable on day 4 and persists until day 18. To identify the phosphatase involved in the reversal from the hyperphosphorylated to the wild-type state, protease inhibitor experiments with LCLs were performed. These identified protein phosphatase 2A (PP2A) as responsible for the dephosphorylation of the hyperphosphorylated form of paratarg-7 (Fig. 6a ). To define the PP2A amount and activation state of PP2A, we performed SDS-PAGE and IEF experiments using lysates of LCLs derived from healthy donors and patients carrying hyperphosphorylated paratarg-7 (Fig. 6A) . The catalytic subunit C of PP2A exists in two forms, one phosphorylated at Y307 and one not. In both patients and controls, the total amount of PP2A in LCLs was not different, but the ratio of phosphorylated to nonphosphorylated PP2A differed strikingly. In patients, the phosphorylated PP2A subunit C was abundant, while in healthy donors the non-phosphorylated form prevailed. Phosphorylation occurs on Y307 of subunit C (Fig. 6B) .
Demonstration of the trimeric complex of paratarg-7 with PKCzeta and PP2A
To demonstrate the direct interaction of PKCzeta and PP2A with paratarg-7 we performed coimmunoprecipitation experiments using LCLs. Using recombinant FLAG-tagged paratarg-7 as bait we detected PKCzeta and PP2A in the immunocomplex formed with paratarg-7 (Fig.   7 ), indicating that both enzymes interact with paratarg-7 and both regulate the phosphorylation state of this protein. PKCzeta was detected in 6/8 and PP2A in all eight autoantigenic paraproteins targets tested (Tab. 1).
Discussion
Our study yielded several significant results: 1 st , we demonstrated that hyperphosphorylation of paratarg-7 is due to a single additional phosphorylation at Ser17; 2 nd , the kinase PKCzeta is involved in the hyperphosphorylation of most, and the phosphatase PP2A in the dephosphorylation of paratarg-7 and all other autoantigenic targets of paraproteins molecularly defined to date; 3 rd , while no differences in PKCzeta could be shown between carriers of the hyperphosphorylated and wild-type paratarg-7, the subunit C of PP2A was shown to be phosphorylated and hence inactive, thus being unable to reverse the hyperphosphorylated state of paratarg-7, which can be induced in carriers of wtP-7, to the wild-type state. Finally, our data suggest that inactivation of PP2A is a mechanism playing a general role in the pathogenesis of MGUS/MM/MW cases far beyond those for whom an autoantigenic target could be identified to date.
Peptidase treatment using trypsin and chymotrypsin on total blood lysates or LCLs followed by immunological detection led to the identification of the phosphorylation site in the epitope region defined before as amino acids 16 to 25 of paratarg-7. By expression of site-directed mutagenized FLAG-tagged fragments of paratarg-7 in HEK293 cells a single additional phosphorylation at amino acid Ser17 was shown to be responsible for the hyperphosphorylation of paratarg-7 in patients with a paratarg-7 specific paraprotein compared to carriers of wild-type paratarg-7. With additional phosphorylation at other sites of the paratarg-7 molecule excluded, this finding demonstrates that the hyperphosphorylation of Ser17 is responsible for the immunogenicity of this paraproteins-binding epitope.
By complementation assays we found that the phosphatase activity was reduced in carriers of pP-7 leading to the assumption that two enzymes are involved in the generation of the hyperphosphorylated state of paratarg-7 and that one of these enzymes appears to be modified in its reactivity when compared to healthy donors. This conclusion led to the necessity to identify the kinase and the phosphatase responsible for the phosphorylation state of paratarg-7.
We were able to identify PKCzeta, an atypical kinase, as responsible for the phosphorylation of most, and PP2A, the most abundant phosphatase in mammalian cells, as responsible for the dephosphorylation of all hyperphosphorylated autoantigenic targets of paraproteins defined to date. Detailed analysis of PKCzeta derived from patients and healthy controls showed no differences with respect to DNA sequence, copy number or expression level in PBMCs and LCLs of patients and healthy donors. Similarly, no differences between carriers of wild type and hyperphosphorylated paratarg-7 were found for the enzymes involved in the signaling pathway upstream of PKCzeta, namely PI3K (Fig. 3) and PTK1 (data not shown) . . The diversity of its subunits provides a large spectrum of PP2A isoforms and enables PP2A to be selective and to affect a wide range of different functions within the cell.
While no difference in the total amount of PP2A message and protein in LCLs was found between patients with wild-type and hyperphosphorylated PP2A, the phosphorylation state of PP2A subunit C was found to be modified. In contrast to healthy donors, all patients with a paraprotein targeting the described autoantigens showed a more intense phosphorylation at (37°C 48 h) the samples were subjected to IEF followed by immunodetection of FLAGtagged paratarg-7 using FLAG antibodies. In lane 1b dephosphorylation of hyperphosphorylated paratarg-7 was observed, while in 1c no dephosphorylation was detected, indicating a compromised dephosphorylation in carriers of hyperphosphorylated paratarg-7.
In the reverse approach using wild-type FLAG-tagged paratarg-7 as acceptor and LCL extracts (2a-c) as donors the upper band representing hyperphosphorylated paratarg-7 was only detected when extracts derived from LCLs of the patient carrying hyperphosphorylated paratarg-7 were used as donors (2c). the dephosphorylation resulting in the appearance of hyperphosphorylated paratarg-7. NIPP1 (10 mM; e) had no effect. NIPP1 is a specific inhibitor of protein phosphatase 1 (PP1); ocadaic acid at 10 nM inhibits both PP1 and PP2A, while at concentrations equal or below 0.1 nM it inhibits only PP2A. B: Analysis of PP2A subunit C derived from MM/MGUS patients and healthy donors: LCLs were subjected to IEF followed by immunodetection using PP2A subunit C antibodies (1:1000; A) or pY307 specific antibodies ( 
Figure 7
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